BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Sativex (Nabiximols) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Sativex (Nabiximols)\, from ClinicalTrial
 s.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05629702-7008@assetmemo.bio
DTSTAMP:20261121T005638Z
DTSTART;VALUE=DATE:20271007
DTEND;VALUE=DATE:20271008
SUMMARY:Sativex (Nabiximols): Phase 2 readout est. (NCT05629702)
DESCRIPTION:Sativex (Nabiximols)\, phase 2.\nStudy: ARISTOCRAT: Blinded Tri
 al of Temozolomide +/- Cannabinoids\nEstimated primary completion: 7 Octob
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/nabiximols#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05629
 702
URL:https://assetmemo.bio/drug/nabiximols#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05351801-7008@assetmemo.bio
DTSTAMP:20261121T005638Z
DTSTART;VALUE=DATE:20280929
DTEND;VALUE=DATE:20280930
SUMMARY:Sativex (Nabiximols): Phase 2 readout est. (NCT05351801)
DESCRIPTION:Sativex (Nabiximols)\, phase 2.\nStudy: Proof of Concept Trial 
 of Cannabis Derivatives in Neuropathic Pain\nEstimated primary completion:
  29 September 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/n
 abiximols#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT05351801
URL:https://assetmemo.bio/drug/nabiximols#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
